Pharming Group (XAMS:PHARM) Deferred Tax : €0.0 Mil (TTM As of Mar. 2025)

View and export this data going back to 1998. Start your Free Trial

What is Pharming Group Deferred Tax?

Change In Deferred Tax represents future tax liability or asset, resulting from temporary differences between book (accounting) value of assets and liabilities, and their tax value. This arises due to differences between financial accounting for shareholders and tax accounting.

Pharming Group's change in deferred tax for the three months ended in Mar. 2025 was €0.0 Mil. Its change in deferred tax for the trailing twelve months (TTM) ended in Mar. 2025 was €0.0 Mil.

Pharming Group Deferred Tax Historical Data

The historical data trend for Pharming Group's Deferred Tax can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharming Group Deferred Tax Chart

Pharming Group Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Deferred Tax

Get a 7-Day Free Trial

Pharming Group Quarterly Data
	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Deferred Tax	Get a 7-Day Free Trial															-	-	-	-	-

Pharming Group Deferred Tax Calculation

Deferred Tax for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.0 Mil.

Pharming Group Deferred Tax Related Terms

Thank you for viewing the detailed overview of Pharming Group's Deferred Tax provided by GuruFocus.com. Please click on the following links to see related term pages.

Pharming Group Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharming Group (XAMS:PHARM) » Definitions » Deferred Tax

Comparable Companies

Traded in Other Exchanges

PHAR:USA PHGUF:USA 0QCO:UK PHG:Germany PHGN:Germany

Address

Darwinweg 24, Leiden, ZH, NLD, 2333 CR

Website

https://www.pharming.com

Pharming Group is a biopharmaceutical company. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome. In addition, the firm's development pipeline includes KL1333, a potential first-in-disease asset for mitochondrial DNA-driven primary mitochondrial diseases. The company's reportable segments are RUCONEST, which derives maximum revenue, Joenja, U.S., and Europe and the Rest of the World (RoW). Geographically, it derives maximum revenue from the United States.

Pharming Group Headlines

No Headlines